hepatocellular carcinoma
Conditions
Interventions
Sponsors
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years, male and female (calculated on the date of signing the informed consent); 2. Hepatocellular carcinoma patients diagnosed by histopathology and/or cytology: 1)Not suitable for surgery and / or local treatment; 2)Progress after surgical and/or topical treatment. 3. Liver function Child-Pugh score <= 7 points; 4. ECOG PS 0-1; 5. BCLC staging: B/C; 6. Plan to use apatinib monotherapy or apatinib in combination with other treatments; 7. Voluntary participation in the study, signing informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Exclude patients with contraindications to anti-angiogenic drugs: 1) The patient has hypertension and cannot be controlled by antihypertensive medication; 2) Urine routinely shows protein positive >= ++; 3) A variety of factors affecting oral medications (unable to swallow, chronic diarrhea, intestinal obstruction, etc.); 4) abnormal blood coagulation, bleeding tendency: for example, active ulcers, fecal occult blood (++), etc.; 5) Grade 3-4 cardiac insufficiency (NYHA standard); 6) Severe hepatorenal insufficiency (grade 4); 3. According to the investigator's judgment, there are serious concomitant diseases that endanger the safety of the patient or affect the patient's completion of the study; 4. The estimated survival time is less than 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progress Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Objective response rate;Time to tumor progression;Disease control rate;Quality of Life Score; | — |
Countries
China
Contacts
Public ContactErlei Zhang
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Outcome results
None listed